tbuckley/cabot-search huggingface dataset:
Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An <scp>EAACI</scp> Taskforce on Immunopharmacology position paper
Authors: Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Antonios G. A. Kolios, Francesca Levi‐Schaffer, Giuseppe Nocentini, Oscar Palomares, Pier Giorgio Puzzovio, Frank A. Redegeld, Betty C. A. M. van Esch, Cristiana Stellato
Journal: Allergy (2018)

Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health. Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens. On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact. Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development. SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs. Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.
Hypothermia treatment does not help traumatic brain injury, study finds
Authors: Zosia Kmietowicz
Journal: BMJ (2018)

Brain cooling does not benefit people who have a brain injury, a randomised study has found, and it should no longer be used in this context, researchers have advised.1

Prophylactic hypothermia has been thought to help reduce the cerebral inflammatory and biochemical cascades associated with traumatic brain injuries and to improve neurological outcomes in patients, but evidence has been conflicting. A 2007 meta-analysis gave a low grade recommendation for using prophylactic hypothermia after severe traumatic brain injury, although the largest randomised controlled trial included in the review showed no benefit. And a trial this year found that hypothermia for …
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230
Authors: Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, Anna Moseley, David J Porter, Prudence A Francis, Lori J Goldstein, Henry L Gomez, Carlos S Vallejos, Ann H Partridge, Shaker R Dakhil, Agustin A Garcia, Julie R Gralow, Janine M Lombard, John F Forbes, Silvana Martino, William E Barlow, Carol J Fabian, Lori M Minasian, Frank L Meyskens, Richard D Gelber, Gabriel N Hortobagyi, Kathy S Albain
Journal: JNCI Journal of the National Cancer Institute (2018)

Abstract Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I–IIIA estrogen receptor–negative, progesterone receptor–negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% to 19.2%, respectively; odds ratio = 2.34; 95% CI = 1.07 to 5.11; P = .03). Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P = .09) and overall survival (HR = 0.45; 95% CI = 0.19 to 1.04; P = .06). In this long-term analysis of POEMS/S0230, we found continued evidence that patients randomly assigned to receive goserelin + chemotherapy were not only more likely to avoid premature menopause, but were also more likely to become pregnant without adverse effect on disease-related outcomes.
MA16.04 Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations
Authors: M. Offin, M. Tenet, R. Shen, N. Rekhtman, H. Rizvi, M. Hellmann, M. Arcila, M. Ladanyi, C. Rudin, M. Kris, H. Yu
Journal: Journal of Thoracic Oncology (2018)
Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
Authors: A. Nogueira-Rodrigues, A.C. de Melo, A.F.D.C. Calabrich, E. Cronenberger, K.L. Torres, F. Damian, R. Cossetti, C.R.A.S. De Azevedo, A.J. da Fonseca, Y. Nerón, J.S. Nunes, A. Lopes, F. Thomé, R. Leal, G. Borges, P.R.S. Nunes Filho, F. Zaffaroni Caorsi, R.D.S. Freitas, G. Werutsky, F.C. Maluf
Journal: Annals of Oncology (2018)
Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
Authors: Y.-J. Bang, E. Van Cutsem, C.S. Fuchs, A. Ohtsu, J. Tabernero, D.H. Ilson, W.J. Hyung, V.E. Strong, T.O. Goetze, T. Yoshikawa, L.H. Tang, P.M.T. Hwang, D. Adelberg, K. Shitara
Journal: Annals of Oncology (2018)
The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC
Authors: I. Jancewicz, N. Rusetska, A. Armatowska, M. Stachowiak, K. Pogoda, A. Niwińska, W. Olszewski, Z.I. Nowecki, T.J. Sarnowski, E. Sarnowska, J.A. Siedlecki
Journal: Annals of Oncology (2018)
Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Authors: M. Iafolla, C. Yang, V. Chandran, M. Pintilie, A. Hansen, P. Bedard, S. Lheureux, A. Spreafico, A. Razak, P. Ohashi, S. Hakgor, A. Giesler, T. Pugh, L.L. Siu
Journal: Annals of Oncology (2018)
Autologous dendritic-cell vaccine based on cancer-testis antigens “CaTeVac” in the treatment of soft tissue sarcoma
Authors: N. Pipia, I.A. Baldueva, T.L. Nekhaeva, A.V. Novik, A.B. Danilova, N.A. Avdonkina, S.A. Protsenko, Y.I. Komarov, D.V. Girdyuk, A.P. Oganesyan, A.M. Belyaev
Journal: Annals of Oncology (2018)
Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia
Authors: Katie Dorothy Dale, James McCracken Trauer, Pete J. Dodd, Rein M.G.J. Houben, Justin Timothy Denholm
Journal: European Respiratory Journal (2018)

Migration is a key driver of tuberculosis (TB) in many low-incidence settings, with the majority of TB cases attributed to reactivation of latent TB (LTBI) acquired overseas. A greater understanding of LTBI risk in heterogeneous migrant populations would aid health planning. We aimed to estimate the LTBI prevalence and distribution among locally born and overseas-born Australians. Annual risks of TB infection estimates were applied to population cohorts (by country of birth, year of arrival and age) in Australian census data in 2006, 2011 and 2016. Both the absolute number and proportion of Australian residents with LTBI increased from 4.6% (interquartile range (IQR) 4.2–5.2%) in 2006 to 5.1% (IQR 4.7–5.5%) in 2016, due to the increasing proportion of the population born overseas (23.8% in 2006 to 28.3% in 2016). Of all residents estimated to have LTBI in 2016; 93.2% were overseas born, 21.6% were aged &lt;35 years and 34.4% had migrated to Australia since 2007. The overall prevalence of LTBI in Australia is low. Some residents, particularly migrants from high-incidence settings, may have considerably higher risk of LTBI, and these findings allow for tailored public health interventions to reduce the risk and impact of future TB disease.
Staging and Restaging for Hepatocellular Carcinoma: Solution of Confusion?
Authors: Teh‐Ia Huo, Po‐Hong Liu, Chia‐Yang Hsu
Journal: Hepatology (2018)

The authors have reported that 68.3% (82/120) of patients required renal replacement therapy (RRT).RRT would be a confounding factor for comparing the response of terlipressin and noradrenaline due to a decrease in creatinine levels postdialysis.Can the authors clarify regarding the time points used for assessment of response to terlipressin or noradrenaline among those patients who received RRT?We would also like to highlight an error in figure 3A.
Devil hepatitis D: an orphan disease or largely underdiagnosed?
Authors: Heiner Wedemeyer, Francesco Negro
Journal: Gut (2018)

Hepatotropic viruses can infect hepatocytes causing a host defence reaction and subsequently scaring of the liver—if the infection is not cleared. The threats of chronic viral hepatitis partially vanished due to the revolution of antiviral treatment options first for hepatitis B and more recently for hepatitis C. Persistent HCV infection can nowadays be cleared with direct acting antiviral agents leading to impressive improvements in the clinical long-term outcome with reduced incidences of hepatic decompensation and hepatocellular carcinoma. Similarly, durable suppression of HBV replication has been shown to prevent disease progression and even to normalise life expectancy unless hepatocellular carcinoma appears.1 Unfortunately, the scenario is completely different for hepatitis D virus (HDV) infection. Coinfection of HBsAg-positive individuals with HDV causes the most severe form of chronic viral hepatitis with earlier development of liver cirrhosis, higher incidence of hepatocellular carcinoma and increased liver-related and overall mortality.2 3 In addition, treatment options for hepatitis D are currently limited. Pegylated interferon alpha has been shown to suppress HDV replication in about 25% of patients but only a minority of patients can be treated with interferon-based therapies and late relapses after initial viral control occur frequently.4 Still, the extent of the global disease burden caused by HDV infection is a matter of debate. The WHO Global Hepatitis Report 2017 highlighted the issue of uncertainty regarding the HDV burden.5 While both the European Medicines Agency and the Food and Drug Administration granted new compounds to treat hepatitis D an orphan drug status (meaning that less than 5 or less than 7.5 out …
P1.14-17 Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model
Authors: S. Padda, Y. Gokmen-Polar, S. Badve, S. Vasista, K. Basu, A. Kumar, S. Vali, T. Abbasi, H. Wakelee
Journal: Journal of Thoracic Oncology (2018)
P2.04-22 Dendritic Cell Based Immunotherapy in Stage IIB-IIIA Non-Small Cell Lung Cancer Patients: 10-Years Experience.
Authors: N. Khranovska, O. Skachkova, O. Gorbach, V. Sovenko, A. Ganul, M. Inomistova, V. Orel
Journal: Journal of Thoracic Oncology (2018)
Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600–mutant high-grade glioma (HGG) or low-grade glioma (LGG)
Authors: D. Hargrave, O. Witt, K. Cohen, R. Packer, A. Lissat, U. Kordes, T.W. Laetsch, L. Hoffman, A. Lassaletta, N.U. Gerber, S. Gilheeney, S. Holm, C. Kramm, D. Sumerauer, C. Reitmann, M.W. Russo, E. Bouffet
Journal: Annals of Oncology (2018)
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study
Authors: M. Honda, C. Matsuda, C. Tanaka, K. Kondo, T. Takahashi, C. Kosugi, Y. Tokunaga, H. Takemoto, H.M. Kim, J. Sakamoto, K. Oba, H. Mishima
Journal: Annals of Oncology (2018)
Identification of prognostic and predictive factors for durvalumab efficacy by modeling of tumor response and overall survival (OS) in patients with non-small cell lung cancer (NSCLC)
Authors: Y. Zheng, R. Narwal, C. Jin, P. Baverel, A. Gupta, P. Mukhopadhyay, B.W. Higgs, L. Roskos
Journal: Annals of Oncology (2018)
Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa
Authors: Giovanni A. M. Povoleri, Estefania Nova-Lamperti, Cristiano Scottà, Giorgia Fanelli, Yun-Ching Chen, Pablo D. Becker, Dominic Boardman, Benedetta Costantini, Marco Romano, Polychronis Pavlidis, Reuben McGregor, Eirini Pantazi, Daniel Chauss, Hong-Wei Sun, Han-Yu Shih, David J. Cousins, Nichola Cooper, Nick Powell, Claudia Kemper, Mehdi Pirooznia, Arian Laurence, Shahram Kordasti, Majid Kazemian, Giovanna Lombardi, Behdad Afzali
Journal: Nature Immunology (2018)
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
Authors: S. Pilotto, G. Grizzi, I. Sperduti, M. Simbolo, C. Vicentini, A. Caliò, M. Caccese, A. Mafficini, L. Carbognin, V. Corbo, A. Gkountakos, A. Santo, M. Infante, M. Brunelli, A. Scarpa, G. Tortora, E. Bria
Journal: Annals of Oncology (2018)
Regional diastolic dysfunction in post-infarction heart failure: role of local mechanical load and SERCA expression
Authors: Åsmund T Røe, Marianne Ruud, Emil K Espe, Ornella Manfra, Stefano Longobardi, Jan M Aronsen, Einar Sjaastad Nordén, Trygve Husebye, Terje R S Kolstad, Alessandro Cataliotti, Geir Christensen, Ole M Sejersted, Steven A Niederer, Geir Øystein Andersen, Ivar Sjaastad, William E Louch
Journal: Cardiovascular Research (2018)

Regional heterogeneities in contraction contribute to heart failure with reduced ejection fraction (HFrEF). We aimed to determine whether regional changes in myocardial relaxation similarly contribute to diastolic dysfunction in post-infarction HFrEF, and to elucidate the underlying mechanisms. Using the magnetic resonance imaging phase-contrast technique, we examined local diastolic function in a rat model of post-infarction HFrEF. In comparison with sham-operated animals, post-infarction HFrEF rats exhibited reduced diastolic strain rate adjacent to the scar, but not in remote regions of the myocardium. Removal of Ca2+ within cardiomyocytes governs relaxation, and we indeed found that Ca2+ transients declined more slowly in cells isolated from the adjacent region. Resting Ca2+ levels in adjacent zone myocytes were also markedly elevated at high pacing rates. Impaired Ca2+ removal was attributed to a reduced rate of Ca2+ sequestration into the sarcoplasmic reticulum (SR), due to decreased local expression of the SR Ca2+ ATPase (SERCA). Wall stress was elevated in the adjacent region. Using ex vivo experiments with loaded papillary muscles, we demonstrated that high mechanical stress is directly linked to SERCA down-regulation and slowing of relaxation. Finally, we confirmed that regional diastolic dysfunction is also present in human HFrEF patients. Using echocardiographic speckle-tracking of patients enrolled in the LEAF trial, we found that in comparison with controls, post-infarction HFrEF subjects exhibited reduced diastolic train rate adjacent to the scar, but not in remote regions of the myocardium. Our data indicate that relaxation varies across the heart in post-infarction HFrEF. Regional diastolic dysfunction in this condition is linked to elevated wall stress adjacent to the infarction, resulting in down-regulation of SERCA, disrupted diastolic Ca2+ handling, and local slowing of relaxation.
XmaI-RRBS DNA methylation screening resolves breast cancer epigenetic heterogeneity
Authors: A.S. Tanas, T. Kekeeva, V.O. Sigin, E.B. Kuznetsova, E. Poddubskaya, I. Trotsenko, D.V. Zaletaev, V.V. Strelnikov
Journal: Annals of Oncology (2018)
bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Authors: Z. Wang, H. Qin, M. Wang, J. Gong, X. Wang, J. Li, J. Gao, Z. Li, D. Wang, S. Cai, Y. Bai, L. Xiong, F. Li, L. Shen
Journal: Annals of Oncology (2018)
Mussel-inspired conductive nanofibrous membranes repair myocardial infarction by enhancing cardiac function and revascularization
Authors: Yutong He, Genlan Ye, Chen Song, Chuangkun Li, Weirong Xiong, Lei Yu, Xiaozhong Qiu, Leyu Wang
Journal: Theranostics (2018)

The controversy between polypyrrole's (Ppy) biocompatibility and its aggregation on nanofibers impedes application of conductive Ppy-incorporated nanofibers to create engineered cardiac microenvironments.The purpose of this study was to fabricate a functional scaffold for engineering cardiac patches (ECP) using a high concentration of methyl acrylic anhydride-gelatin (GelMA)-Ppy nanoparticles, musselinspired crosslinker, and electrospun (ES)-GelMA/polycaprolactone (PCL) nanofibrous membrane.Methods: First, spherical GelMA-Ppy nanoparticles were obtained when the methacrylate groups of GelMA formed a self-crosslinked network through oxidative polymerization of Ppy.Second, GelMA-Ppy nanoparticles were uniformly crosslinked on the ES-GelMA/PCL membrane through mussel-inspired dopamine-N'N'-methylene-bis-acrylamide (dopamine-MBA) crosslinker.Finally, the feasibility of the dopa-based conductive functional ECP scaffold was investigated in vitro and in vivo.Results: The GelMA-Ppy nanoparticles displayed excellent biocompatibility at a high concentration of 50 mg/mL.The massive GelMA-Ppy nanoparticles could be uniformly distributed on the ES nanofibers through dopamine-MBA crosslinker without obvious aggregation.The high concentration of GelMA-Ppy nanoparticles produced high conductivity of the dopamine-based (dopa-based) conductive membrane, which enhanced the function of cardiomyocytes (CMs) and yielded their synchronous contraction.GelMA-Ppy nanoparticles could also modify the topography of the pristine ES-GelMA/PCL membrane to promote vascularization in vitro.Following transplantation of the conductive membrane-derived ECP on the infarcted heart for 4 weeks, the infarct area was decreased by about 50%, the left ventricular shortening fraction percent (LVFS%) was increased by about 20%, and the neovascular density in the infarct area was significantly increased by about 9 times compared with that in the MI group. Conclusion:Our study reported a facile and effective approach to developing a functional ECP that was based on a mussel-inspired conductive nanofibrous membrane.This functional ECP could repair infarct myocardium through enhancing cardiac function and revascularization.
Survival effect of lncRNA-X expression in EGFR-mutant adenocarcinoma
Authors: Y. Nakano, K. Isobe, A. Kakimoto, H. Kobayashi, K. Kaburaki, G. Sano, S. Sakamoto, Y. Takai, N. Tochigi, T. Mikami, A. Iyoda, S. Homma
Journal: Annals of Oncology (2018)
MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC
Authors: A. Januszewski, Y.Z. Zhang, W. Chang, U. Laggner, A. Bowman, T. Adefila-Ideozu, W. Cookson, M. Moffatt, A. Nicholson, A. Bowcock, S. Popat
Journal: Journal of Thoracic Oncology (2018)
OA07.02 ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI
Authors: O.S.h. Chan, K.C. Lam, J. Li, F. Choi, C. Wong, A. Chang, F. Mo, K. Wang, R. Yeung, T. Mok
Journal: Journal of Thoracic Oncology (2018)
P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
Authors: B. Han, B. Zhang, J. Xu, Y. Zhang, X. Zhang, T. Chu, S. Wang, R. Qiao, J. Qian, J. Lu, L. Zhang
Journal: Journal of Thoracic Oncology (2018)
Microsatellite instability is associated with distinct clinical and molecular characteristics in early colon cancer: Analysis of a molecular registry of the AIO colorectal study group - Colopredict Plus
Authors: A. Reinacher-Schick, H. Juette, S. Noepel-Duennebacke, D. Arnold, N. Basara, H. Boehner, T. Dahm, I. Feder, T. Herzog, W. Hiller, L. Mueller, L. Engel, M. Senkal, C. Teschendorf, G. Trenn, B. Verdoodt, H. Wolters, W. Uhl, A. Tannapfel
Journal: Annals of Oncology (2018)
Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience
Authors: V. Dadduzio, M.D. Rizzato, G. Ramondo, C. Vivaldi, M. Milella, G. Brandi, S. Cereda, S. Murgioni, G.G. Cardellino, R. Filippi, D. Santini, G. Pasquini, R. Intini, V. Vaccaro, A. Palloni, M. Reni, G. Musettini, E. Gringeri, C. Aliberti, V. Zagonel
Journal: Annals of Oncology (2018)
Measles Outbreak in a Highly Vaccinated Population — Israel, July–August 2017
Authors: Eva Avramovich, Viki Indenbaum, Meital Haber, Ziva Amitai, Evgeny Tsifanski, Sahar Farjun, Alona Sarig, Adi Bracha, Karina Castillo, Michal Perry Markovich, Inbal Galor
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

On August 6, 2017, the Israeli Defense Force Public Heath Branch (IDFPHB) was notified of two suspected measles cases. IDFPHB conducted an epidemiologic investigation, which identified nine measles cases in a population with high measles vaccination coverage. All measles patients had signs and symptoms consistent with modified measles (i.e., less severe disease with milder rash, fever, or both, with or without other mild typical measles symptoms). A total of 1,392 contacts were identified, and 162 received postexposure prophylaxis (PEP) with measles-mumps-rubella (MMR) vaccine; the remaining contacts were followed for 21 days (one incubation period). No tertiary cases were identified.
P2.09-14 The Detection of EGFR Gene Mutation from Washing Solution of Devices used for the Bronchoscopic Examination
Authors: R. Nakahara, T. Kasai, Y. Kamiyama, Y. Nakamura, T. Sugiyama, I. Wakamatsu, N. Hoshi, K. Nakano, H. Matsuguma
Journal: Journal of Thoracic Oncology (2018)
P1.17-07 The Prognostic Value of Volumetric Changes of the GTV Measured on CBCT During Radiotherapy for CCRT in NSCLC Patients
Authors: M. Kwint, B. Stam, J. Belderbos, M. La Fontaine, E. Aalbersberg, M. Rossi, J. Sonke, I. Walraven
Journal: Journal of Thoracic Oncology (2018)
HALO 107-201: A phase Ib, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: M. Baumgart, M. Muhsin, W. Wu, N. Gabrail
Journal: Annals of Oncology (2018)
Discovery of novel germline genetic biomarkers of melanoma recurrence impacting exonic and long non-coding RNA (lncRNA) transcripts
Authors: T. Kirchhoff, D. Simpson, T. Hekal, R. Ferguson, E. Kazlow, U. Moran, Y. Lee, A. Izsak, M.A. Wilson, R. Shapiro, A. Pavlick, I. Osman
Journal: Annals of Oncology (2018)
P1.14-18 The Promising Role of Sunitinib Rechallenge in Heavily Pre-Treated Thymic Carcinoma: A Case Report
Authors: G. Palmieri, M. Ottaviano, M. Tortora, P. Perrone, C. Rea, S. De Placido, M. Giuliano
Journal: Journal of Thoracic Oncology (2018)
A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Authors: P.G. Corrie, R.N. Matin, A. Gupta, W. Qian, S. Wordsworth, E. Gibbons, A. Chhabra, C. Harman, C. Mather, M.R. Middleton
Journal: Annals of Oncology (2018)
P2.06-31 Inhibition of Heat Shock Protein 70 Function Suppresses Proliferation in Mesothelioma Cells
Authors: K. Sakai, M. Inoue, H. Nishimura, S. Mikami, Y. Kuwabara, A. Kojima, M. Toda, Y. Kobayashi, S. Kikuchi, Y. Hirata, H. Kyoyama, G. Moriyama, A. Gemma, K. Uematsu
Journal: Journal of Thoracic Oncology (2018)